UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
4d
Clinical Trials Arena on MSNGilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
A new study by UCSF researchers reveals that long-acting injectable treatments offer a promising alternative for HIV patients who find it challenging to adhere to daily pill regimens. This ...
Patients who struggle to take daily HIV pills can benefit from long-acting ... the UCSF HIV/AIDS clinic at Zuckerberg San Francisco General Hospital. They studied data from 370 patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results